Current Urology Reports

, Volume 5, Issue 4, pp 274–279

The role of 5-α-reductase inhibition as monotherapy in view of the MTOPS data

Authors

  • Jaspreet S. Sandhu
    • Brady Prostate Center, Department of UrologyNew York Presbyterian Hospital
  • Alexis E. Te
    • Brady Prostate Center, Department of UrologyNew York Presbyterian Hospital
Article

DOI: 10.1007/s11934-004-0050-6

Cite this article as:
Sandhu, J.S. & Te, A.E. Curr Urol Rep (2004) 5: 274. doi:10.1007/s11934-004-0050-6

Abstract

Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of α blockers and 5-α-reductase inhibitors. Data suggest that 5-α-reductase inhibitors can prevent progression of BPH and reduce the risk of BPH-related surgery, especially in men with large-volume prostates. Results from the largest randomized, prospective, placebo-controlled trial, the Medical Therapy of Prostatic Symptoms trial, have been presented. These results support the notion of using 5-α-reductase inhibitors for the prevention of BPH progression and BPH-related surgery. Furthermore, long-term 5-α-reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms.

Download to read the full article text

Copyright information

© Current Science Inc 2004